exemestane,tamoxifen,triptorelin
azurity pharmaceuticals,astrazeneca,pfizer
['breast', 'soft trial']
interesting analysis of the soft trial by the md. lauren claire young women diagnosed with breast cancer have &lt;40 years vs &gt;40 years, have significantly more luminal b and &gt;40 years vs &gt;40 years with luminal a have a higher risk of recurrence.
#asco23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.